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As chemotherapy and other sophisticated treatment strategies evolve and the number of survivors of 
long-term childhood cancer grows, the long-term complications of treatment and the cancer itself are 
becoming ever more important. One of the most important but often neglected complications is osteoporosis 
and increased risk of fracture during and after cancer treatment. Acquisition of optimal peak bone 
mass and strength during childhood and adolescence is critical to preventing osteoporosis later in life. 
However, most childhood cancer patients have multiple risk factors for bone mineral loss. Cancer itself, 
malnutrition, decreased physical activity during treatment, chemotherapeutic agents such as steroids, 
and radiotherapy cause bone mineral deficit. Furthermore, complications such as growth hormone 
deficiency and musculoskeletal deformity have negative effects on bone metabolism. Low bone mineral 
density is associated with fractures, skeletal deformity, pain, and substantial financial burden not only 
for childhood cancer survivors but also for public health care systems. Thus, it is important to monitor 
bone health in these patients and minimize their risk of developing osteoporosis and fragility fractures 
later in life.
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Introduction
Overall long-term survival of childhood cancer patients is increasing and is esti  mated 
to be 74% to 80% because of early detection, evolution of chemotherapy, im  proved 
surgical techniques, refined radiation therapy, and hematopoietic stem cell trans  plantation 
(HSCT)
1,2). It is estimated that 1 of every 640 young adults in the USA is a childhood 
cancer survivor (CCS)
3). However, long-term survivors of childhood cancer (LTSCC) 
face increased risks of various health problems resulting from treatment or the cancer 
itself. These include secondary cancers, cardiac dysfunction, infertility, growth failure, 
endocrine deficiencies, renal damage, pulmonary toxicity, hearing loss, neuropsychiatric 
problems, obesity, and musculoskeletal abnormalities
4,5). Among these, osteoporosis is of 
great importance because it can lead to fractures, pain, deformity, gait abnormality, and 
substantial financial burden
6-8).
Osteoporosis was previously considered a disease of the elderly but is now considered 
to have a pediatric origin
6). Individuals who fail to achieve optimal peak bone mass 
(PBM) and strength during childhood and adolescence are more likely to develop oste-
oporosis later in life
9). LTSCC fail to achieve optimal PBM because of the cancer itself, 
malnutrition during chemotherapy, and decreased physical activity. The onset of most 
childhood cancers is in the second decade of life, when nearly 43% to 66% of maximal 61 http://dx.doi.org/10.3345/kjp.2013.56.2.60
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adult bone mineral density (BMD) is gained
10). Thus, LTSCC have 
a high prevalence of osteoporosis or low BMD, even in early 
adul  thood
11-22). Radiotherapy, chemotherapy, and hormone 
deficiencies are frequently cited as risk factors for osteoporosis 
and fractures in LTSCC
13,18,23,24).
In this review, we address the pathophysiology, prevalence, 
screening, and management of osteoporosis in CCSs. The ob-
jective is to raise awareness among pediatricians of the risk of 
osteoporosis in CCS and the 2008 Children’s Oncology Group 
(COG) long-term follow-up (LTFU) guidelines for bone mineral 
deficits
13).
Pathophysiology of BMD deficits in CCSs
The mechanism causing BMD deficits in CCS is multifactorial. 
It depends on cancer type, therapeutic modalities such as 
chemotherapeutic agents and radiation, and the occurrence 
of endocrine complications like growth hormone deficiency 
(GHD) and hypogonadism. In addition, other factors such as age 
at cancer diagnosis, sex, genetic predisposition, nutrition, and 
lifestyle affect BMD. 
Cancer itself causes BMD deficits. Ten to twenty percent 
of children with acute lymphoblastic leukemia (ALL) exhibit 
reduced BMD at diagnosis
25,26). Leukemic infiltration of the 
bone and various factors secreted by leukemic cells, such as 
parathyroid hormone (PTH) and PTH-related peptide, were 
suggested as causes of BMD deficit
25). Some osteosarcoma pa-
tients have had BMD deficit in the affected limb, which initially 
presented with bone pain
26). 
Chemotherapeutic agents such as corticosteroids, metho  trexate, 
and alkylating agent are well known to cause BMD deficits 
directly or indirectly. Corticosteroids inhibit new bone formation 
by decreasing osteoblastic activity, including osteocalcin 
production, and by directly increasing osteoclastic bone resorp-
tion
23). Corticosteroids also inhibit 1α-hydroxylation of vitamin 
D and result in impaired intestinal absorption of calcium and 
reduced muscle strength. ALL patients administered a total cor-
ticosteroid dose greater than 9 g/m
2 are more likely to develop 
reduced BMD that does not recover to within normal range 
after treatment
27). High-dose prednisone (≥20 g/m
2) is a risk 
factor for osteopenia in patients with malignant lym  phoma
15). 
Methotrexate also suppresses osteoblast activity and stimu lates 
osteoclast recruitment, resulting in decreased bone forma tion 
and increased bone resorption
28). Higher cumulative doses of 
methotrexate have been associated with a greater in  cidence of 
osteopenia
23). Total doses of more than 4 g/m
2 were associated 
with a high risk of osteopenia and failure to recover to a normal 
BMD after completion of therapy
16,27). Alkylating agents such 
as cyclophosphamide and ifosfamide cause hypogona dism 
and result in decreased BMD. Estrogens play a crucial role in 
achieving and maintaining PBM by preventing bone resorption 
and stimulating growth factors necessary for bone growth
29). 
Androgens seem to have an important role in periosteal apposi-
tion, adding to the biochemical strength of the bone
29). Ifosfa-
mide also induces Fanconi syndrome, which can result in hypo-
phosphatemia and severe metabolic bone disease. Other agents 
such as vincristine, daunorubicin, etoposide, and aspa  raginase 
reduce type I collagen synthesis
30). Vincristine also induces 
neuropathy, which leads to poor balance and increases the risk of 
falls.
Radiation is the most important risk factor for osteoporosis, 
especially in brain tumor survivors
24). Radiation might directly 
affect BMD by damaging the bone marrow stroma
31), but the 
principal cause is assumed to be deficiencies of hormones such 
as growth hormone (GH) and sex steroid
7,17). Cranial and total 
body irradiation (TBI) can lead to GHD and central hypogona-
dism, both of which are associated with BMD deficits
32). Chil  dren 
who received cranial irradiation at a dose of 24 Gy had reduced 
spontaneous and pulsatile GH secretion, while nonir  radiated 
children had normal secretion
13). Fractionated TBI doses of >12 
Gy for transplant conditioning may also result in GHD
13,18). 
Radiation-induced fractures in survivors treated with radiation 
doses of ≥40 Gy have been described
33). 
Endocrine sequelae such as GHD and hypogonadism also 
cause BMD deficits in CCS. GH is important to acquiring ade-
quate PBM and to maintaining bone mass
34). Not only radiation 
but also chemotherapy can cause GHD. Roman et al.
35) reported 
that 44% of a cohort of 25 children who had received chemo-
therapy and surgery for malignant solid tumors developed im-
paired GH secretion. GHD is related to low BMD in both adults 
and children
14,34,36). Baroncelli et al.
36) reported that lumbar 
BMD declined rapidly after discontinuation of GH in patients 
with GHD, compared with controls. We also reported that GH 
replacement was associated with increase in BMD in patients 
with intracranial germ cell tumors
14).
Hypogonadism is often caused by alkylating agents and 
radiation. Gonadotropin deficiency occurs with high-dose 
radiation (≥40 Gy) to the neuroendocrine axis
13). Peripheral 
hypo  gonadism occurs at much lower radiation doses. Ovarian 
dysfunction and premature menopause are associated with 
radiation doses of ≥10 Gy to the ovaries in prepubertal females 
and ≥5 Gy in pubertal females
13,18). In males, higher doses (≥20 
Gy) are required to cause Leydig cell dysfunction with associated 
androgen insufficiency
13,18). 
HSCT is well known to cause BMD deficits. Adult transplanta-
tion studies reported that a 2% to 10% loss of BMD significantly 
increased the risk of fractures
37). Childhood leukemia survivors 
with HSCT had gonadal deficiency and significantly lower 
femoral BMD as adults
38). Patients undergoing HSCT often http://dx.doi.org/10.3345/kjp.2013.56.2.60
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receive multiple agents associated with altered bone metabolism, 
including methotrexate, steroids, TBI, and high-dose alkylating 
agents, as part of their treatment
19). In addition, altered kidney, 
liver, and bowel functions might result in reduced absorption 
and abnormal metabolism of calcium and vitamin D
39). Finally, 
the HSCT procedure itself has been reported to cause severe and 
persistent quantitative and qualitative impairment of osteoblastic 
precursors within the stromal stem cell compartment
38).
Some CCS may fail to achieve optimal PBM. To acquire 
adequate PBM, nutrition and physical activity are essential
9). 
However, most pediatric cancer patients do not regularly con-
sume the recommended daily allowances of nutrients, including 
during cancer treatment. Such patients have been found to have 
altered metabolism of calcium, 1,25-dihydroxyvitamin D, and 
magnesium during prolonged periods of hospitalization and 
immobilization
40,41). During and after treatment, they were less 
involved in physical activities than healthy controls
12,42). Pain 
associated with osteopenia significantly limited physical activity 
in brain tumor survivors
12). Reduced exercise capacity was 
related to decreased bone mineralization in survivors of ALL
42). 
CCS seemed to have a higher prevalence of osteoporosis and 
fractures in males than in females
14,42-44). The longer period of 
pubertal development and partial hypogonadism in boys might 
contribute to this difference between sexes
14,43).
Prevalence of BMD deficits in CCSs
The exact prevalence of osteoporosis and osteopenia in CCS 
is difficult to show, although published studies have identified 
reduced BMD as a common finding in young adulthood. Most 
reports include small numbers of subjects, diverse malignant 
diseases, heterogeneity of therapeutic modalities, various age 
groups, different sites of BMD measurement, and different 
definitions of osteoporosis (Table 1). The Childhood Cancer 
Survivor Study reported results of a questionnaire survey of 
more than 1,600 brain tumor survivors, only 29 of whom had 
osteoporosis
45). However, other studies reported osteoporosis 
or osteopenia in almost half of the CCSs
11-22,46). Therefore, the 
true prevalence of bone mineral loss could be underestimated 
according to methods of BMD evaluation in CCS. 
The terminology and criteria of low BMD are diverse and mixed in 
the literature, although ‘‘low bone density for chro nologic age’’ is 
the preferred wording in CCS studies. World Health Organization 
definitions of osteopenia and osteoporosis are based on T-scores, 
used to compare patients’ BMD with the maximum BMD of young 
adults, and applied only to postme nopausal women. The International 
Society for Clinical Densitometry recommended use of “low bone 
density for chro nologic age” when the BMD Z-score is lower than 
-2.0 for males and females younger than 50 years
47). Wasilewski-
Masker et al.
32) and Sala et al.
15) suggested another criterion: Z-score 
less than -1.0 was defined as low BMD, and Z-score less than -2.5 
as significantly low BMD. In our previous study, Z-scores of <-2.0 
indicated osteoporosis, and Z-scores ≥-2.0 and <-1.0 indicated 
osteopenia in subjects younger than 20 years
14). For convenience, 
we used the terms “osteopenia” and “osteoporosis” when searching 
the literature. The prevalence rates of osteoporosis and osteopenia in 
CCS are summarized in Table 1. 
1. ALL
At diagnosis, 10% to 20% of children with ALL exhibited re-
duced BMD at the lumbar spine
7,48). During therapy, additional 
bone mineral loss occurred, especially in early periods of 
intensified treatment, and approximately 50% of children had 
a reduction in BMD. Halton et al.
48) reported that fractures oc-
curred in 39% of children during treatment. Reports of results 
from after completion of therapy have been conflicting. Kaste 
et al.
43) reported that ALL patients had a median BMD Z-score 
of -0.78 standard daviation (SD), and 21% had abnormally 
low BMD, compared to 5% in normal populations after 15.9 
years. Hoorweg-Nijman et al.
20) also concluded that bone de-
velopment in patients cured of ALL is disturbed, resulting in a 
significantly reduced BMD. In a 24-year follow-up study, low 
BMD was found to be more prevalent (24%) than expected based 
on population normative data, specifically in men
21). However, 
some reported normal BMD after cessation of ALL treatment
49-51). 
Brennan et al.
52) reported that adult survivors of ALL whose 
treatment included cranial irradiation had reduced BMD, while 
those without cranial irradiation showed normal bone mineral 
apparent density (BMAD)
53). 
2. Lymphoma
Osteopenia (Z-score<-1.00) was found in 41% (9/22) of pati-
ents with Hodgkin’s disease and 50% (10/20) of patients with 
non-Hodgkin’s lymphoma at the lumbar spine after 24.1 and 
14.1 years of follow-up, respectively
15). The use of mechloretha-
mine, oncovin, procarbazine, and prednisone led to decreased 
height and increased body mass index in men and decreased 
total body BMD in women
54). High cumulative dose of cortico-
steroids, especially, was a risk factor for osteopenia
15).
3. Brain tumors
Osteoporosis is a common sequel of therapy in children with 
brain tumors. We previously reported that 25.0% of patients with 
germ cell tumors had osteoporosis and 42.9% had osteopenia 
at 10.9-year follow-up
14). The prevalence of osteoporosis (bone 
mineral contents Z-score<-2.5) in the entire body was more 
than 40% in the irradiated group and 0% in the nonirradiated 
group of patients with posterior fossa tumors or optic glioma
46). 
Barr et al.
12) also reported that BMD decreased at the lumbar 63 http://dx.doi.org/10.3345/kjp.2013.56.2.60
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spine (mean Z-score, -1.05) and femoral neck (mean Z-score, 
-0.84), with an overall osteopenia prevalence of 47.3%, in brain 
tumor survivors. Previous reports have showed that survivors of 
various childhood brain tumors are susceptible to development 
of fractures and early osteoporosis, especially in association with 
the risk factor GHD
17,45).
4. Other solid tumors 
Low BMD in has been reported in survivors of various other 
solid tumors
22). Osteopenia or osteoporosis was reported in 28.3 
% to 65% of survivors of osteogenic sarcoma or Ewing’s sar-
coma
16,55,56). Holzer et al.
16). reported that 65% of osteosarcoma 
patients had BMD deficits at the age of 31±4.2 years, and the 
mean duration of follow-up from diagnosis was 16±2.2 years. 
We also found that 47.5% of long-term survivors of osteosar-
coma had osteoporosis and 30.0% had osteopenia at the age 
of 22.0±5.1 years (unpublished data). A high incidence of 
osteopenia (26%) was found in survivors of Wilms’ tumor
57) and 
Table 1. Prevalence of osteopenia and osteoporosis in childhood cancer survivors  
Cancer type No.
Mean age 
at cancer 
diagnosis 
(yr)
Mean age 
at BMD
evaluation 
(yr)
DXA sites Mean 
Z-score
% of low BMD
(%osteopenia<-1.0
/%osteoporosis<-2.5)
Risk factors for BMD
deficit in the study Reference
All cancers 40 12.7 25.6 LS 2-4
FN
Total body
1/3 D radius
-0.22
-0.68
-0.33
-1.57
NA Gonadal dysfunction Aisenberg et al.
11)
Non-CNS
 cancers
519 4.8 12.1 NA NA 8.1 NA Patterson et al.
69)
ALL 24 6.8 25.1 LS 1-4
FN
1/3 D radius
UD radius
-1.07
-1.07
-1.76
-1.44
(low BMD, Z-score<-2.0)
45.8
Impaired GH secretion Hoorweg-Nijman
 et al.
20)
ALL 74 5.64 30.04 LS 2-4
FN
Total body
0.13
0.18
0.34
24 Ht Z-score≤-1.0 in female 
Male gender
Cranial RTx≥24 Gy 
Low IGF-1 level
Thomas et al.
21)
ALL/NHL 89 4.8 24.7 LS 1-4
Total hip
FN
-0.60
-0.26
-0.22
49 Prophylactic cranial RTx
TBI-conditioned BMT
Male gender at LS
Previous dexamethasone  treatment 
Low final Ht and bone size
Benmiloud et al.
19)
HD
NHL
22
20
14.7
6.1
24.1
14.1
LS
LS
-0.55
-0.83
45.2 High cumulative dose of 
 corticosteroids
Sala et al.
15)
Intracranial
GCT
28 11.6 23.1 LS 1-4
FN
Total body
-1.1
-0.4
-0.8
67.9 (42.9/25.0) Male gender
Low lean mass
Delayed start of adult GH replacement
Kang et al.
14)
Brain tumor
Astrocytoma, 
CRP, GCT, 
Ependymoma 
MBL, PBL
36 8.4 16.9
LS 1-4
Total hip
FN
-0.91
-0.91
-0.83
(osteoporosis, Z-score <-2)
44 (19/25)
59 (42/17)
50 (28/22)
Fracture history
Untreated GHD
Cohen et al.
17)
Osteosarcoma 48 15 31.0 LS 1-4
FN
FT
-0.49
-0.90
-0.47
64.5 (43.7/20.8) Age at surgery
In female, hypoestrogen status
Holzer et al.
16)
Sarcoma
Ewing+OSA
46 13.9 14.3 LS 2-4 -0.14 28.3 (26.1/2.2) Tumor location (lower  extremity) 
  with offloading  recommendation
Muller et al.
56)
Solid tumor
Lymphoma
Sarcoma
WT, NBL
38 8.9 22.0 LS 2-4
Total body
UD+1/3D radius
total hip+FN
NA 34 (24/8) exclude forearm
50 include forearm
No. of chemotherapy drugs Kelly et al.
22)
NBL 27 6.1 6.1 LS2-4
Total body
0.65
0.82
(osteoporosis, Z-score<-2)
26 (11/15)
Advanced stage of NBL with diffuse 
bone and bone marrow metastasis
Al-Tonbary et al.
58)
BMD, bone mineral density; DXA, dual energy X-ray absorptiometry; LS, lumbar spine; FN, femur neck; 1/3 D radius, 1/3 distal radius; NA, not available; CNS, 
central nervous system; ALL, acute lymphoblastic leukemia; UD, ultradistal; GH, growth hormone; Ht, height; RTx, irradiation; IGF-1, insulin-like growth factor 1; NHL, 
non-Hodgkin’s lymphoma; TBI, total body irradiation; BMT, bone marrow transplantation; HD, Hodgkin’s disease; GCT, germ cell tumor; CRP, craniopharyngioma; 
MBL, medulloblastoma; PBL, pineoblastoma; FT, femur total; OSA, osteosarcoma; WT, Wilms’ tumor; NBL, neuroblastoma.http://dx.doi.org/10.3345/kjp.2013.56.2.60
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neuroblastoma
58). Low bone mass may occur in children at initial 
diagnosis of neuroblastoma and before the start of chemotherapy 
or radiotherapy, especially if the disease is at an advanced stage 
with diffuse bone and bone marrow metastases
58).
5. HSCT
HSCT recipients had reduced BMD at multiple skeletal sites 
and BMAD in the spine when compared with controls
59). In a 
prospective study, BMD of the spine and hip gradually decreased 
over 12 to 14 months after allogeneic HSCT
60). Kaste et al.
61) 
reported that after at a median follow-up of 5.1 years, allogeneic 
HSCT recipients had a median BMD Z-score of -0.89, and 14.6% 
had osteopenia. In a 14-year follow-up study, acute leukemia 
patients in the HSCT group had a significantly reduced femoral 
neck BMD (mean BMD Z-score, -0.49) compared with patients 
who did not receive a transplant, and 7.4% of them had a 
history of fracture. Children who were younger at the time of 
transplantation had a significantly higher risk of low spinal 
BMD during adulthood
38). Bone loss seemed to be worse after 
allogeneic HSCT than after autologous HSCT
62), probably because 
of a prolonged and greater cytokine release after transplantation 
and because use of immunosuppressive agents is more important 
after allogeneic transplantation.
Screening and management
The high prevalence of osteoporosis, even in early adulthood, 
in CCS suggests that specific diagnosis and treatment may be 
beneficial, although there is still no consensus on the treatment 
of osteoporosis in the young. The 2008 COG LTFU guide  lines 
recommended a baseline evaluation of BMD by dual-energy 
X-ray absorptiometry or quantitative computed tomography 
at entry into LTFU for patients exposed to metho trexate, cor-
ticosteroids, and HSCT and who have medical conditions such 
as GHD, hypogonadism, delayed puberty, or hyperthyroidism
13). 
Some experts even insist that children with brain cancer should be 
evaluated for BMD immediately, because most cancer treatment 
protocols are risk factors for bone mineral deficit
63). BMD should 
be evaluated with robust nor mative data; fortunately, we have 
normative data for Korean children and adolescents
10). 
The management algorithm for osteoporosis in CCS is shown 
in Fig. 1. All CCS should undergo prophylaxis for bone loss and 
fractures (Table 2). Repeat measurements are not required for 
patients with normal baseline BMD results (BMD Z-score>-1). 
The COG LTFU guidelines recommend 800 to 1,500 mg of 
calcium and 200 IU vitamin D daily intake, through diet or 
supplementation
13). However, pediatricians should be aware 
of the fact that most Korean children and adolescents are not 
receiving the recommended dietary intake of calcium and 
vitamin D
64). Recently, the U.S. Institute of Medicine issued a new 
clinical guideline on vitamin D
65). According to this guideline, 600 
IU vitamin D is needed to maintain 25-hydroxy vitamin D at more 
than 20 ng/mL. Considering the fact that corticosteroids reduce 
intestinal calcium absorption and increase calcium excretion, 
adequate intake of calcium and vitamin D is an important 
prevention strategy. Up to 1,500 to 2,000 IU vitamin D is needed 
in cases of vitamin D deficiency. 
If BMD Z-score is between -1.0 and -2.0, regular follow-
up is required. Treatment of BMD deficits in children includes 
≤ ≤
Fig. 1.  Algorithm to prevent osteoporosis in childhood cancer survivors. LTFU, long-term follow-up; GHD, 
growth hormone deficiency; DXA, dual energy X-ray absorptiometry; BMD, bone mineral density. 65 http://dx.doi.org/10.3345/kjp.2013.56.2.60
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increasing weight-bearing exercise as tolerated, optimizing 
nutritional intake of calcium and vitamin D, nutrient supple-
mentation if dietary intake is insufficient, and treatment of 
conditions that may exacerbate BMD deficit, such as hypo-
gonadism or GHD. Running or jumping has been proven to 
positively affect BMD
8). Supplementation with vitamin D and 
increased calcium intake have been proven to enhance PBM in 
healthy children. Counseling survivors about avoiding smoking, 
alcohol, and caffeine is also important, as all of these can 
exacerbate BMD deficits
66). 
If BMD Z-score is less than -2.0, recurrent fractures, latent 
medical risk factors for decreased BMD, and hormonal risk 
factors such as hypogonadism or GHD should be considered. 
Endocrinology consultation may be advisable. Pediatric endo-
crinologists should thoroughly evaluate BMD and osteoporosis 
risk factors in cancer survivors. They also should consider 
treatment options such as bisphosphonates, although bispho-
sphonates are currently reserved for patients with recurrent 
fractures and clinical trial participants. Only a few publications 
on the use of bisphosphonates in pediatric cancer patients are 
available, but reports of bisphosphonate treatment benefit in 
cancer patients are limited
67,68). Pamidronate caused rapid pain 
relief, gradual improvement of BMD, and improved motor 
function
68). These are promising results, but long-term cont-
rolled studies are needed to assess the risks and benefits of 
bisphosphonates in children with osteoporosis.
Conclusions
Survivors of childhood and adolescent cancers are at risk for 
osteoporosis (or low bone mass for chronologic age) during and 
after completion of therapy. Treatment with corticosteroids, 
methotrexate, or HSCT is associated with an increased risk of 
BMD deficits. Radiation and alkylating chemotherapy increase 
the risk of endocrinopathies that predispose patients to reduced 
BMD. Genetic predisposition and lifestyle may also contribute to 
BMD deficits. Pediatricians should be aware that CCS are at risk 
for osteoporosis and require appropriate early intervention.
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